Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ALX ONCOLOGY HOLDINGS INC (ALXO)

ALX Oncology cuts Q2 net loss to $18.0 million from $25.9 million; cash $153.4 million

Positive Impact 3 of 5 earnings Written later

ALX Oncology reported a second-quarter 2026 GAAP net loss of $18.0 million, or $0.13 per share, down from $25.9 million, or $0.49 per share, a year earlier. The company said cash, cash equivalents and investments were $153.4 million at June 30, 2026, and that this is sufficient to fund planned operations through the first half of 2028. Shareholders also face a larger share count, with weighted-average shares rising to about 135.6 million from 53.4 million.

Key points

  • Q2 2026 GAAP net loss was $18.0 million ($0.13 per share), versus $25.9 million ($0.49 per share) in Q2 2025; the prior-year period included a $3.2 million lease impairment charge.
  • R&D expenses fell to $13.1 million from $18.0 million; G&A expenses were $5.1 million versus $5.5 million.
  • Cash, cash equivalents and investments were $153.4 million at June 30, 2026, up from $48.3 million at December 31, 2025.
  • In June 2026, the company refinanced its $10 million debt with HSBC Ventures USA Inc., with a facility of up to $50 million, of which $10 million is uncommitted.

The filing

CompanyALX ONCOLOGY HOLDINGS INC (ALXO)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:05 AM ET
Accession number0001193125-26-336843

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.